10-03 :: March 2010

nanotimes

Companies

Facts

B

T Pharma, a biopharmaceutical company deve- loping innovative immunotherapies to prevent

cancers caused by the human papillomavirus (HPV), has raised EUR13.1 million in additional funding and

changed its name to Genticel. AGF Private Equity

led the round.

http://www.genticel.com

C

tools RFP-Trap®

hromoTek, a company specializing in bioima- ging reagents, has launched the bioimaging and GFP-Booster. RFP-Trap®

is

used to identify and pull down interaction partners of proteins tagged with RFP (red fluorescent protein) and GFP-Booster restores or increases the GFP (green fluorescent protein) signal in super-resolution micro- scopy. RFP-Trap®

is a versatile tool for biochemical

and cell biological analysis of RFP-tagged fusion proteins in pull down assays (a frequently used in vitro method used to determine physical interaction between two or more proteins).

http://www.chromotek.com

T

he Dow Chemical Company‘s (NYSE:DOW)

North American Technical Service and Global

Research and Development Center for packaging adhesives and coatings will move to Buffalo Gro- ve, Illinois in early April 2010. The expanded Tech Service and R&D Center represents a significant step forward in the company’s commitment to enhance customer support and new product deve- lopment. Buffalo Grove is located in close proximity to Chicago’s O’Hare Airport. The facility has been located in Elgin, Illinois, USA.

http://www.rohmhaas.com

E

purex Films GmbH & Co. KG, a subsidiary of Bayer MaterialScience, will be marketing film

products formerly sold as Walopur® Walotex®

, Platilon® and under the common trade name Platilon® .

“This move will enable Epurex Films, as one of the leading European manufacturers of thermoplastic polyurethane (TPU) films, to work more openly and effectively with its customers, to further increase awareness of the name Platilon®

21

and to strengthen its

position on the international markets,” says Rüdiger Heins, Head of Sales and Marketing at Epurex Films.

Examples of demanding applications include breatha- ble but watertight membranes for outdoor clothing, special plasters that create a healthy wound climate and encourage rapid healing, and intermediate layers for bulletproof glass.

http://www.functional-films.com

F

lamel Technologies (NASDAQ:FLML) announced its financial results for the fourth quarter and year

ended December 31, 2009. Results during the fourth quarter: • Pfizer exercised the option to license the Medusa® platform for development of an improved intrave- nous formulation of an already-marketed molecule acquired in its merger with Wyeth;

• The Company signed new feasibility studies app- lying the Medusa®

with two top-ten pharmaceutical companies;

• The Company announced that the Agence Na- tionale de Recherche sur le SIDA et les Hépatites Virales (ANRS) initiated a twelve week study com- paring two dosage forms of IFN-alpha XL plus riba- virin versus Peg-Intron® Hepatitis C patients.

platform to three new molecules

plus ribavirin in genotype 1